High performance, diagnostic rapid point-of-care (POC) flow-based tests can quickly deliver reliable results in challenging settings. When designing a new test and designing out a component in an existing test-what are the key considerations and what will be needed in the future?
Commercializing a test or assay as quickly as possible is critical to success. Find out how diagnostic design services, lyophilization and custom capabilities can provide capacity, resources and expertise to improve speed to market now and in the future.
Strategic collaboration enables the development of diagnostic tests, assays and service for a wide range of applications. Hear about recent collaborations that have resulted in successful test development and set a path for future development.
High throughput NGS techniques are revolutionizing genomics from massively parallel whole genome sequencing to targeted sequencing approaches. Find out how to simplify your sequencing approaches for more detailed data, better diagnosis, and more targeted treatments to address current and future demands.
Recent technological advancements have made single-cell omics an increasingly powerful tool for diagnosis, treatment response prediction, and treatment selection, particularly for cancer. Learn about the opportunities for improving results in this growing field.
Recent years have seen the development and adaptation of several approaches for nucleic acid isolation, aiming to improve speed, throughput, and reproducibility. Find out how to optimize results, particularly for liquid biopsy and viral samples now and in the future.
Sessions will be available for on-demand viewing immediately following the live broadcast.
Click on 'Watch on Demand' button to view the webinars within the summit or click on each webinar below to go directly to that webinar.
Advancing the development and manufacture of therapeutics
Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit cytiva.com for more.
Improving access to life-changing therapies that transform human health
Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Our job is to supply the tools and services they need to work better, faster and safer, leading to better patient outcomes.
Cytiva is a global life sciences leader with over 7000 associates across 40 sites who are dedicated to our vision to improve access to life-changing therapies that transform human health. As a trusted partner to customers that range in scale and scope, Cytiva brings efficiencies to research and manufacturing workflows, ensuring the development, manufacture and delivery of transformative medicines to patients.
Find out more at Cytiva.com
Anja is a senior application specialist for Biacore systems with over 17 years’ experience supporting and educating Biacore users in Germany. Anja’s interests focus on development of new or challenging applications using optical biosensors including the analysis of complex sample matrices. Anja’s background is in biotechnology engineering and she received her PhD in molecular Biology from Humboldt University in Berlin.
Gabriel Fernandez de Pierola is the Genomics & Diagnostic Solutions General Manager at Cytiva, since 2017. He is responsible for the development and commercialization of products and services that enable automatable, cost-effective and reliable technologies for kit developers and end users mainly focusing on genomics. Previously he was the Global Commercial Finance manager for the GE Healthcare Bioprocess business. Gabriel started his career in the GE Capital Financial Management Program in 1999. Gabriel holds a Bachelor of Business Administration degree from ICADE (Spain) and Reims Management School (France).
Dr. Christopher Fronczek is currently an Application Scientist in Research and Development for BioDot, Inc. He received his B.S. in Biological Engineering in 2010 from Louisiana State University and Ph.D. in Biomedical Engineering in 2013 from the University of Arizona. He has also worked towards the development of point-of-care diagnostics and has worked as a Postdoctoral Fellow in Analytical Chemistry. Since joining BioDot in 2016, his area of expertise has been low-volume dispensing and liquid handling for biosensors and various other point-of-care diagnostic devices.
Priya Hari is a Postdoctoral Genomics Research Fellow at Cytiva with advanced skills in research, cell culture and science communication and is heavily endorsed by the University of Edinburgh. Priya holds a BSc in Medical Biochemistry and a PhD in Cellular Senescence and Tumour Suppression. Alongside her academic achievements, Priya has also been an active STEM Ambassador for over eight years and has published five papers in a range of application areas.
Dr. Hochleitner is a cell and molecular biologist and has covered different roles in the field of membrane research and development, and developing diagnostic tests on solid surfaces. He is working in the field of lateral flow tests for more than 25 years.
Part of the Senior Management team within the Whatman business area of Cytiva, with overall responsibility for the performance of a large portfolio of products and services, primarily focused on the diagnostic rapid testing market. Experience of involvement with diagnostic development companies for over 5 years and part of the Cytiva (formerly GE Life Sciences) business for over 9 years.
Marilena Loizidou is Deputy Director of the Division of Surgery and Interventional Science, Head of Department of Surgical Biotechnology and a Professor of Cancer Nanotechnology at University College London (UCL).
Marilena Loizidou uses nanotechnology tools in cancer pharmacology research. Her main focus has been in the field of novel imaging and targeted therapeutics in solid tumors, mainly colorectal cancer, with a focus on the role of the fibrotic cancer stroma. Marilena co-invented tumoroids, 3D in vitro cultures of cancer which mimic the composition and architecture of solid tumors. Today tumoroids are being developed as platforms for therapeutics and for stratified medicine.
Tom Lyons is Custom Projects Leader at Cytiva, managing custom Sera-Mag™ formulations and conjugation projects. Since graduating from the University of East Anglia with a Masters in Analytical Chemistry with Forensic Sciences in 2008, Tom has gained experience in many research and development roles including British BioCell where he developed lateral flow immunodiagnostic devices and Binx Healthcare (formerly Atlas Genetics), where he developed enzyme stabilization formulations and managed the bulk reagent formulating process. Tom is trained in PRINCE2 project management with a focus on the transfer to manufacture of formulations for InVitro Diagnostic Devices with CE and FDA regulator frameworks.
Sean Mackay co-founded and leads IsoPlexis as CEO. IsoPlexis’ mission is to provide widely accessible cellular proteomics to speed personalized, curative medicines. The company focuses on shifting paradigms in cell and gene therapy, cancer immunology, and infectious disease towards more patient specific, long lasting treatments. IsoPlexis’ easy-to-use instrumentation and software have won numerous awards and are used globally to advance precision medicine.
Previously, Sean helped incubate Kleiner Perkins-backed Lifesquare, which connected patients, payers, and providers through sharing essential healthcare information. Additionally, through work at Lazard and with several early-stage ventures, he developed a passion for helping life sciences and medical device companies manage in times of strategic change, to deliver their highly needed products to the clinical ecosystem. Sean has co-authored several publications centered around immune medicines and holds patents for a number of single-cell products worldwide.
Pieter Mestdagh, PhD is a Senior Scientist at Biogazelle, as well as Associate Professor at the Faculty of Medicine and Health Sciences, Ghent University, Belgium. He holds Masters degrees in industrial Engineering and Biochemistry (2004), and Bioscience Engineering and Cell and Gene Biotechnology (2006), as well as PhD in Biomedical Sciences (2011). He is the author of more than 100 scientific articles in international journals, as well as the owner of six European Patents.
Dr. Zahidul Mondle is a Lead Technical Product Specialist at Cytiva. He has decades of hands on experience in developing molecular diagnostics, lateral flow assays, and immunoassays. He worked at Pfizer in vaccine development as an analytical scientist before joining Cytiva. Zahidul hold an MBA and a PhD in Biochemistry.
Dr. Chris Norey is an R&D Leader with over 25 years’ experience in the life sciences industry after gaining a PhD in Biochemistry and Molecular Biology. For the past 10 years Dr. Norey has lead teams responsible for launching over 25 new products, including instrumentation and reagent and consumable products, most recently the Sera-Xtracta™ genomic and cell free nucleic acid isolation kits. He currently leads the genomics R&D team at Cytiva focused on delivering tools for the growing field of genetic based diagnostic applications.
David Raw is the Supplier Risk Management Leader at Cytiva (formerly GE Healthcare Life Sciences) and has worked in supply and sourcing roles in healthcare for more than 13 years. David is passionate about positioning security of supply as a value-based differentiator and a clear value driver of success for patients and Biopharma customers. David holds an MBA in Business Strategy, Supply Chain Management and is also a student mentor/coach at Birmingham University in the UK.
Monika Seidel is the scientific lead on new product development from conception throughout feasibility to manufacturing handover. She has extensive knowledge of liquid biopsy-based diagnostic applications including explain ddPCR (ddPCR) and NGS and expertise in molecular biology, biochemistry, immunology-related techniques, mass spectrometry and stem cell biology. Monika’s research has focused on dissecting molecular mechanisms of human diseases in the field of genomics, proteomics and lipidomics including explain iPSc based(iPSc) modelling of motor neuron degeneration, structure function relationship studies in Ryanodine Receptor 2 associated with sudden cardiac death and siRNA-based high content and high throughput screening for identification of molecular targets and signaling pathways of anti-cancer drugs. She has an M.Sc. degree in Biotechnology, B.Sc. in Organic Chemistry and holds a PhD in Medical Sciences from the University of Cardiff, UK.
Graduating from Aberystwyth University with Joint Hons Microbiology & Biochemistry, Jon started his career as a Microbiologist at Revlon Manufacturing UK Ltd where he was first involved in developing rapid tests. This was followed by several years in R&D at companies developing ATP bioluminescence based assays before moving into Project Management in 1998. For the last 20 years Jon has held commercial roles in the Biotechnology, Pharma, IVD and Life Science sectors and is currently the Head of Contract Sales at Abingdon Health.
Abingdon Health is a technology-enabled lateral flow diagnostics company providing leading-edge rapid testing solutions to a multi-industry, global client base. Abingdon Health provides lateral flow assay development and smartphone reader solutions alongside Europe’s largest rapid test manufacturing capacity. A multi-disciplinary team forms the foundations of our services and a partnership-led approach alongside a focus on operational excellence produces reliable products irrespective of their complexity. Established supply chain and manufacturing processes are tailored to assay specifications and market demand for continuity of supply.
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK. The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK. The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost. Avacta’s proprietary pre|CISIONTM targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONTM drug candidate, a targeted form of the standard-of-care Doxorubicin, into the clinic by the first half of 2021. By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta’s diagnostics business unit works with partners world-wide to develop Affimer proteins for evaluation by those third parties with the objective of establishing royalty bearing license deals with a particular focus on the diagnostics sector. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.
BioDot is the leading provider of automated, ultralow-volume, non-contact fluid dispensing platforms for R&D applications and commercial-scale manufacturing across diagnostics and life sciences, medical products and applied industrial markets. Its technologies are integral to production of point-of-care diagnostics for infectious diseases, allergy tests and diabetes maintenance as well as veterinary medicine and environmental applications. BioDot, founded in 1994, is based in Irvine, California and has international offices in Europe and Asia.
Biogazelle is a Contract Research Organization (CRO) specializing in high-value applications to support pharmaceutical research, clinical trials and diagnostic test development. We hold a unique forefront position in the application of quantitative PCR, digital PCR and dedicated RNA sequencing workflows, optimized for quantification of coding and non-coding genes, on precious clinical samples such as liquid biopsies and formalin-fixed, paraffin-embedded (FFPE) tissues. Our aim is to accelerate the development of therapeutics, including small molecules, RNA targeted drugs, and adoptive cell therapies.
IsoPlexis (www.isoplexis.com) is dedicated to accelerating the fight against cancer and a range of the world's toughest diseases with its uniquely correlative, award-winning, single-cell proteomics systems. By revealing unique immune biomarkers in small subsets of cells, we are advancing immunotherapies and targeted therapies to a more highly precise and personalized stage. Our integrated systems, named #1 innovation by the Scientist Magazine and Fierce, are used globally to advance the field of immune biology and biomarkers as we generate solutions to overcome the challenges of complex diseases.
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events